Entrada Therapeutics Advances ELEVATE-45-201 Clinical Study to 10 mg/kg Dosage Cohort

An independent safety data monitoring committee has recommended that Entrada Therapeutics proceed to the second cohort of its ELEVATE-45-201 clinical study at an increased dosage of 10 mg/kg. This decision follows a review of safety data collected from the initial group of participants in the ongoing trial.

The committee’s recommendation allows the company to escalate the dose for the next phase of the study, which evaluates the safety and tolerability of the treatment. Researchers established the 10 mg/kg dosage level after reviewing the findings from the first cohort, where participants received a lower initial dose. The study continues to monitor patient responses as the trial advances to this higher concentration, adhering to the established safety protocols set by the committee.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI